2019 IPO

Personalis Stock

Contract research organization and genome-scale diagnostics services company

Sign up today and learn more about Personalis Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Personalis Stock

Personalis combines expertise both in the technology of sequencing and in interpretation, with an extensive history of peer reviewed publication and commercial success. Broad adoption of medical genome interpretation will require accuracy befitting regulatory approval, both in variant detection and interpretation. More than half of the founding team are MDs, and this reflects the company's commitment to serious medically-focused results, at quality standards eventually suitable for regulatory approval and insurance reimbursement. The team includes experienced PhD scientists, who know that the research community also cares deeply about accuracy, thoroughly substantiated and peer-reviewed. Personalis has exclusively licensed key intellectual property originating in the labs of the founders. Lastly, the Personalis team includes business people with decades of experience in genetic analysis, who know that the democratization of genome sequencing will also require high-quality customer support for interpretation, lab by lab, genome after genome.

Funding History

August 2011$20.0M
October 2013$22.0M
January 2015$33.0M


Chief Executive Officer

John West

Vice President Finance and Administration

Carol J. Tillis

Senior Director of Genomic Services

Christian Haudenschild

Chief Science Officer

Richard Chen

Co-founder and Scientific Advisor

Atul Butte

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: